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Background: Chronic asthma is often associated with neutrophilic infiltration in the airways. Neutrophils contain
elastase, a potent secretagogue in the airways, nonetheless the role for neutrophil elastase as well as neutrophilic
inflammation in allergen-induced airway responses is not well defined. In this study, we have investigated the
impact of neutrophil elastase inhibition on the development of allergic airway inflammation and airway
hyperresponsiveness (AHR) in previously sensitized and challenged mice.
Methods: BALB/c mice were sensitized and challenged (primary) with ovalbumin (OVA). Six weeks later, a single
OVA aerosol (secondary challenge) was delivered and airway inflammation and airway responses were monitored 6
and 48 hrs later. An inhibitor of neutrophil elastase was administered prior to secondary challenge.
Results: Mice developed a two-phase airway inflammatory response after secondary allergen challenge, one
neutrophilic at 6 hr and the other eosinophilic, at 48 hr. PAR-2 expression in the lung tissues was enhanced
following secondary challenge, and that PAR-2 intracellular expression on peribronchial lymph node (PBLN) T cells
was also increased following allergen challenge of sensitized mice. Inhibition of neutrophil elastase significantly
attenuated AHR, goblet cell metaplasia, and inflammatory cell accumulation in the airways following secondary
OVA challenge. Levels of IL-4, IL-5 and IL-13, and eotaxin in BAL fluid 6 hr after secondary allergen challenge were
significantly suppressed by the treatment. At 48 hr, treatment with the neutrophil elastase inhibitor significantly
reduced the levels of IL-13 and TGF-β1 in the BAL fluid. In parallel, in vitro IL-13 production was significantly
inhibited in spleen cells from sensitized mice.
Conclusion: These data indicate that neutrophil elastase plays an important role in the development of allergic
airway inflammation and hyperresponsiveness, and would suggest that the neutrophil elastase inhibitor reduced
AHR to inhaled methacholine indicating the potential for its use as a modulator of the immune/inflammatory
response in both the neutrophil- and eosinophil-dominant phases of the response to secondary allergen challenge.
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Bronchial asthma is a complex syndrome characterized
by airway obstruction, airway inflammation and airway
hyperresponsiveness (AHR) [1]. In the pathogenesis of
asthma, various inflammatory cells contribute to the de-
velopment of AHR and allergic airway inflammation. A
common theory is that the disease results from chronic
airway inflammation leading to AHR and reversible air-
way obstruction [2]. In adults with stable asthma treated
with inhaled corticosteroids, ~40% have eosinophilic
asthma, whereas 25% have neutrophilic asthma [3], and
asthmatics with neutrophilic airway inflammation also
have AHR, along with many other phenotypes of
asthma. Neutrophils are one of the pro-inflammatory
cell types whose role in the pathology of asthma has
been emphasized recently. Acute severe asthma has been
shown to be associated with neutrophilic infiltration of
the airways [4,5]. Neutrophils were reported to predom-
inate in fatal attacks of short duration [3], and in the
early stages of status asthmaticus, neutrophilic infiltra-
tion of the airways was demonstrated [6,7]. However, the
specific role of neutrophils in the pathogenesis of asthma
has not been clarified.
We have previously shown important differences when
a primary challenge approach was compared with mice
that had previously been sensitized and challenged and
later provoked with a single airway challenge (secondary
challenge) [8]. It has been shown that neutrophils in-
crease in bronchoalveolar lavage (BAL) fluid 6 hours
after provocation, whereas eosinophils increase 48 hours
after provocation [9]. This model perhaps more closely
mimics the human situation of previous exposure than
primary models of acute exposure.
Among the neutrophil proteases, elastase has the
greatest potential to cause tissue injury and alter air-
way function [10]. Neutrophil elastase has been shown
to play an important role in neutrophil-endothelial ad-
hesion and extravasation elicited by pro-inflammatory
mediators [11]. Association of neutrophil elastase activ-
ity with asthmatic subjects has been reported [12-14].
Recent study demonstrated that significant increases of
sputum IL-8 and neutrophil elastase protein and IL-8
receptor gene expression were shown in the neutro-
philic asthma and systemic inflammation was increased
in patients with neutrophilic airway inflammation and
associated with worse clinical outcomes [15]. Goblet
cell degranulation was inhibited when neutrophil re-
cruitment was prevented or when neutrophil elastase
activity was inhibited after antigen challenge of sensi-
tized guinea pigs [16,17]. In Ascaris suum allergen-
induced sheep model, Fujimoto et al. reported that the
neutrophil elastase inhibitor, ONO-5046, reduced asth-
matic responses but did not affect the number of eosi-
nophils and lymphocytes in BAL fluid [18]. In thisstudy, we evaluated the role of neutrophil elastase in
allergen-induced inflammation and AHR on a back-
ground of previously established disease, provoked by
secondary challenge.
In established asthma, the importance of neutrophil
elastase on allergen-induced AHR and airway inflamma-
tion has not been elucidated. In addition, the mechan-
isms whereby neutrophil elastase affects allergic airway
responses and inflammation remain to be identified. In
the present study, to define the role of neutrophil elas-
tase following established allergen-induced AHR and
inflammation and response to secondary challenge, we
utilized sivelestat, a specific synthetic inhibitor of neu-
trophil elastase.
Material and methods
Animals
Female BALB/c mice (8–10 wk of age) were purchased
from Charles River Japan, Inc. (Yokohama, Japan). The
mice were maintained on diets free of ovalbumin (OVA).
All experimental animals used in this study were housed
under constant temperature and light cycles and experi-
ments performed under a protocol approved by the In-
stitutional Animal Care and Use Committee of Okayama
University Medical School (Okayama, Japan).
Sensitization and airway challenge
Mice were sensitized by intraperitoneal injection of 20 μg
of OVA (Grade V; Sigma-Aldrich, St. Louis, MO) emulsi-
fied in 2.25 mg aluminum hydroxide (AlumImuject;
Pierce, Rockford, IL) in a total volume of 100 μL on days
0 and 14. Mice were challenged (primary challenge) via
the airways with OVA (1% in saline) for 20 min on days
28, 29 and 30 using ultrasonic nebulizer. On day 72, mice
received a single secondary challenge via the airways
with 1% OVA for 20 min. Mice were studied 6 and 48 hr
after the secondary challenge [8].
Administration of the neutrophil elastase inhibitor
Sivelestat (N-[2-[4-(2,2-dimethylpropionyloxy)-phenylsulfo-
nylamino]benzoyl] aminoacetic acid) is a specific synthetic
inhibitor of neutrophil elastase (Ono Pharmaceutical Co.,
Osaka, Japan). Mice received sivelestat, 100 mg/kg/day
intraperitoneally, from day 68 through to the day of study.
Control groups of mice received saline in the same fashion.
Determination of airway responsiveness
A flexiVent small-animal ventilator (SCIREQ, Montreal,
PQ, Canada) was used to assess airway function
(Snapshot) in anesthetized (intraperitoneal injection of
sodium pentobarbital, 70 mg/kg), mechanically venti-
lated animals, measuring changes in lung resistance
(RL) in response to increasing doses of inhaled methacho-
line (MCh) [18]. Airway responsiveness was assessed
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in airway function after challenge with aerosolized
MCh administered for 10 s (60 breaths/min, tidal vol-
ume: 20 ml/kg) in increasing concentrations (0, 3.125,
6.25, 12.5 and 25 mg/ml). Baseline RL values in re-
sponse to saline at 6 and 48 hr were first determined.
The data of RL was continuously collected for up to
3 min and maximum values were taken.
Bronchoalveolar lavage
After assessment of AHR, lungs were lavaged via the tra-
cheal tube with Hanks’ balanced salt solution (2 × 1 ml,
37°C). The volume of collected BAL fluid was measured
in each sample and the number of BAL fluid cells was
counted. Cytospin slides were stained and differentiated
in a blinded fashion by counting at least 200 cells under
light microscopy. BAL fluid supernatants were collected
and stored at −30°C until measurement [19].
Histological and immunohistochemistry studies
After obtaining the BAL fluid, lungs were fixed in 10%
formalin. Blocks of lung tissue were cut around the
main bronchus and embedded in paraffin blocks. Tis-
sue sections 4 μm thick were affixed to microscope
slides and deparaffinized. Lung sections were stained
with hematoxylin-eosin (H&E) especially for analyzing
the difference between eosinophils and neutrophils
(final magnification:x1000), periodic acid Schiff (PAS) for
identification of mucus-containing cells (goblet cells) (final
magnification:x1000) and granulocyte-differentiation anti-
gen (Gr-1) monoclonal antibody (BioLegend, San Diego,
CA) [20] for detection of neutrophil infiltration (final mag-
nification:×400) and confirmed H&E stained data. In
hematoxylin-eosin and anti-Gr-1 monoclonal antibody
stained lung section, the number of eosinophils, lympho-
cytes, and neutrophils per square millimeter in the peri-
bronchial and perivascular tissue were analyzed using NIH
Image Analysis system. More than 10 bronchioles in a
minimum of 10 high-power fields per lung tissue were
randomly examined in a blinded fashion. The num-
bers of mucus-containing cells were counted in more
than 10 bronchioles in the 10 high-power fields per
animal by measuring the length of epithelium defined
along the basement membrane and luminal area using
the NIH Image Analysis system [20]. Some lungs were
stored at −80°C in paraffin blocks and stained with
proteinase-activated receptor 2 (PAR-2) antibody
(Santa Cruz Biotechnology, Santa Cruz, CA), and
were examined under light microscopy (final magnifi-
cation:x400). PAR-2 positive cells per square milli-
meter in the lung tissue were analyzed using NIH
Image Analysis system. More than 10 bronchioles in a
minimum of 10 high-power fields per lung tissue were
randomly examined in a blinded fashion.Measurement of cytokine, chemokine and growth factor
The levels of cytokine, chemokine and growth factor in the
BAL fluid and cell culture supernatants were measured by
ELISA according to the manufacturer’s directions as previ-
ously described [21]. The limits of detection were 2 pg/ml
for IL-4, KC and IFN-γ, 7 pg/ml for IL-5, 1.5 pg/ml for IL-
13 and MIP-2, 3 pg/ml for eotaxin 4.61 pg/ml for TGF-β1
(R&D Systems, Minneapolis, MN).
Measurement of serum anti-OVA antibody
Serum anti-OVA IgE antibody levels were measured by
ELISA (DS pharma biomedical, Osaka, Japan), 6 and
48 hr after the last airway challenge as previously
described [22]. The antibody titers of samples were
related to pooled standards that were generated in the
laboratory and expressed as ELISA (ng/ml). The limits
of detection were 2.7 ng/ml.
Flow cytometry
To stain intracellular protease-activated receptor 2
(PAR-2) in the peribronchial lymph nodes (PBLN), fix-
ation and permeabilization of the cells were performed
with BD cytofix/cytoperm kit (BD Biosciences Pharmin-
gen, San Diego, CA, USA), and then incubated with
anti-human PAR-2 mAb (Santa Cruz Biotechnology)
according to the manufacturer’s directions. 1×106 cells
were incubated with PerCP-conjugated anti-CD3, PE-
conjugated anti-human PAR-2 mAb or control antibody,
FITC-conjugated anti-CD4 antibodies (BD Biosciences),
and then 2×104 cells were analyzed by flow cytometry
(FACScalibur, Becton Dickinson Immunocytometry Sys-
tems) as previously described [23].
Cell preparation and culture
Spleens from secondary challenged mice were removed
and placed in PBS. Tissue was dispersed into single-cell
suspensions, and mononuclear cells (MNC) were puri-
fied by Ficoll-Hypaque gradient centrifugation (Sigma-
Aldrich) and cells (4×105) were cultured for 24 hr in
96-well round-bottom plates in the presence or absence of
OVA (100 μg/ml) as previously described [23].
Statistical analysis
All results were expressed as mean ± SD. Multiple compar-
isons were performed by ANOVA following Newman-
Keuls’s multiple comparison tests. The comparisons
between two groups were performed by Mann–Whitney
U-test. The p-value for significance was set at 0.05.
Results
Inhibition of neutrophil elastase attenuates AHR and
airway inflammation 6 hr after secondary challenge
Mice sensitized and challenged (primary) and mice chal-
lenged only were re-challenged (secondary) with OVA.
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challenged with OVA and treated with vehicle devel-
oped AHR compared to the non-sensitized but OVA
challenged and re-challenged mice. When mice were
treated with sivelestat, AHR were significantly reduced
compared to vehicle saline-treated mice (Figure 1A).
In parallel, inflammatory cell recruitment into the air-
ways was increased 6 hrs after secondary airway chal-
lenge of previously sensitized and challenged animals
(Figure 1B). Increased total cell numbers were largely
due to increased numbers of neutrophils in BAL fluid
(47% of total BAL fluid cells). When mice were treated
with sivelestat, the numbers of eosinophils and lym-
phocytes were decreased significantly compared with
vehicle-treated mice.
Lung inflammation 6 hr after secondary challenge
In previous studies, the development of AHR was
associated with inflammatory changes in lung tissue
[24]. To determine if sivelestat affected inflammatory
changes in the lung, we assessed tissue inflammation
6 hr after secondary OVA challenge. Hematoxylin-
eosin and anti-Gr-1 monoclonal antibody stained
lung tissue showed significant increases of neutrophil
and lymphocyte numbers in peribronchial inflamma-
tion in previously sensitized and challenged animals#
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Figure 1 Neutrophil elastase inhibitor attenuates AHR 6 hr after seco
values to increasing concentrations of inhaled MCh were measured in non
OVA), OVA-sensitized/OVA-challenged mice receiving saline (OVA/OVA/veh
(OVA/OVA/Sivelestat/OVA). Results for each group are expressed as the me
obtained 6 hr after secondary challenge. Results for each group are expres
(P<0.05) between PBS/OVA/OVA/vehicle and OVA/OVA/OVA/vehicle. #Signi
and OVA/OVA/Sivelestat/OVA.compared to the non-sensitized mice. Mice treated
with sivelestat demonstrated reduced the numbers of
lymphocytes in lung tissue (Figure 2A, 2B, 2C).
Lung sections were stained with PAS to identify
mucus-containing cells in the airway epithelium
(Figure 2D). A significant increase in numbers of PAS
positive cells was found in previously sensitized and
challenged mice compared with non-sensitized but re-
challenged mice. Treatment with sivelestat significantly
reduced the number of PAS positive cells per millimeter
of basement membrane (Figure 2E).
Cytokines, chemokines and growth factor levels in BAL
fluid 6 hr after secondary challenge
Six hr after secondary allergen challenge, BAL fluid was
obtained to assess cytokine and chemokine levels. After
secondary challenge, Th2 (IL-4, IL-5 and IL-13) cyto-
kines were all increased in sensitized and challenged
mice treated with vehicle compared to non-sensitized
mice. Treatment with sivelestat significantly reduced the
levels of IL-4, IL-5 and IL-13 (Figure 3). Levels of
eotaxin, KC, and MIP-2 in BAL fluid were also increased
in sensitized and challenged mice treated with saline
compared to non-sensitized mice, and treatment with
Sivelestat significantly reduced the level of eotaxin but
not KC or MIP-2 (Figure 3).#
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Figure 2 Treatment with sivelestat reduces airway inflammation 6 hr after secondary challenge. (A) H&E–stained lung tissue (final
magnification:x400). (a) PBS/OVA/vehicle/OVA, (b) OVA/OVA/vehicle/OVA, (c) OVA/OVA/Sivelestat/OVA. (B) Inflammatory cell numbers in the
peribronchial and perivascular tissue were measured (final magnification:x1000). (C) Anti-Gr-1 monoclonal antibody stained lung tissue (final
magnification:x400). (a) PBS/OVA/vehicle/OVA, (b) OVA/OVA/vehicle/OVA, (c) OVA/OVA/Sivelestat/OVA. (D) Treatment with sivelestat suppresses
goblet cell metaplasia. PAS staining was performed to identify mucus-containing cells in the airway epithelium (final magnification:x1000). (a)
PBS/OVA/vehicle/OVA, (b) OVA/OVA/vehicle/OVA, (c) OVA/OVA/Sivelestat/OVA. (E) The number of mucus-positive cells. Data represent the mean
± SD. (n = 8 in each group). *Significant differences (P<0.05) between PBS/OVA/vehicle/OVA and OVA/OVA/vehicle/OVA. #Significant differences
(P<0.05) between OVA/OVA/vehicle/OVA and OVA/OVA/Sivelestat/OVA.
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challenge attenuates lung allergic responses 48 hr after
secondary challenge
We previously showed that at 48 hr after secondary al-
lergen challenge, the inflammatory reaction and AHR
developing after primary challenge resolved but that the
re-challenge induced a strong inflammatory reaction
with development of AHR [8]. Indeed, as observed with
the increases in AHR 6 hr after the secondary challenge,these increases in AHR 48 hr after the secondary chal-
lenge were also significant (Figure 4A). Under these con-
ditions, treatment with sivelestat significantly prevented
the increases in AHR.
At 48 hr, increased total cell numbers were largely
due to increased numbers of eosinophils and lympho-
cytes in the recovered BAL fluid. Administration of
sivelestat at the time of the secondary challenge led to
a significant decrease in eosinophil numbers in BAL
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Figure 3 Treatment with sivelestat alters cytokine, chemokine, and growth factor levels in BAL fluid 6 hr after secondary challenge.
The levels of (A) IL-4, (B) IL-5, (C) IL-13, (D) TGF-β1, (E) Eotaxin, (F) KC, and (G) MIP-2 in BAL fluid were measured. The results for each group are
expressed as the mean ± SD. (n = 16 in each group). *Significant differences (P < 0.05) between PBS/OVA/vehicle/OVA and OVA/OVA/vehicle/OVA.
#Significant differences (P < 0.05) between OVA/OVA/vehicle/OVA and OVA/OVA/Sivelestat/OVA.
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ted with vehicle showed remarkable accumulation of
the numbers of eosinophils and lymphocytes in lung
tissue at 48 hr and administration of sivelestat signifi-
cantly reduced the numbers of eosinophils and lym-
phocytes in lung tissue (Figure 4C, 4D, 4E) as well as
numbers of goblet cells (Figure 4F, 4G).
Forty-eight hr after the secondary challenge, IL-13
and IL-5 levels were increased in sensitized and chal-
lenged mice treated with vehicle compared to non-
sensitized mice. Treatment with sivelestat significantly
reduced IL-13 levels in BAL fluid. Levels of TGF-β1,
and MIP-2 in BAL fluid were also increased in sensi-
tized and challenged mice treated with vehicle com-
pared to non-sensitized mice, and treatment with
sivelestat significantly reduced the levels of TGF-β1
(Figure 5).
Serum anti-OVA IgE antibody levels after secondary
challenge
6 hr and 48 hr after secondary allergen challenge,
serum was obtained to assess OVA-specific IgE levels.
Levels of OVA-specific IgE were significantly increased
in sensitized and challenged mice treated with vehicle
compared with non-sensitized but challenged mice.
Treatment with sivelestat did not affect serum OVA-
specific IgE levels, likely since initial sensitization and
challenge were completed before administration of the
inhibitor (Table 1).PAR-2 expression in lung tissue
PAR-2 has been reported to be one of the receptors
for neutrophil elastase [25], and is expressed on a var-
iety of cells including airway epithelial cells, fibro-
blasts, myocytes, sensory neurons, and bronchial and
vascular smooth muscle [26,27]. PAR-2 was detected
intracellularly in eosinophils but at undetectable levels
on the cell surface. However, once these few receptors
became activated, PAR-2 was redistributed from intra-
cellular stores to the surface of the cell [28]. In lung
tissue assessed for PAR-2 staining, non-sensitized and
challenged mice showed few PAR-2 positive cells
(Figure 6A(a), 6A(b), 6B), whereas sensitized and chal-
lenged and both 6 and 48 hr after secondary allergen
challenged mice showed increased numbers of PAR-2
positive cells (Figure 6A(c), 6A(e), 6B). Treatment
with sivelestat did not affect the number of PAR-2
positive cells (Figure 6A(d), 6A(f ), 6B).
PAR-2 expression on PBLN T cells
To determine the expression of PAR-2 in T cells, percen-
tages of PAR-2-positive CD3+ and CD4+ T cells in PBLN
were assessed by intracellular staining. As shown in
Figure 6C, increased numbers of PAR-2 positive CD3+
and CD4+ T cells were observed in the PBLN of sensi-
tized and challenged and secondary challenged mice.
Sivelestat did not have any significant effect on the num-
ber of PAR-2 positive CD3+ and CD4+ T cells in the
PBLN (data not shown).
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Figure 4 (See legend on next page.)
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Figure 4 Treatment with sivelestat reduces AHR and airway inflammation 48 hr after secondary challenge. (A) Changes in RL 48 hr after
secondary challenge. Results for each group are expressed as the mean ± SD. (n = 16 in each group). (B) Cell composition in BAL fluid. Results for
each group are expressed as the mean ± SD. (n = 16 in each group). (C) H&E–stained lung tissue (final magnification:x400). (a) PBS/OVA/vehicle/
OVA, (b) OVA/OVA/vehicle/OVA, (c) OVA/OVA/Sivelestat/OVA. (D) Inflammatory cell numbers in the peribronchial and perivascular tissue (final
magnification:x1000). (E) Anti-Gr-1 monoclonal antibody stained lung tissue (final magnification:x400). (a) PBS/OVA/vehicle/OVA, (b) OVA/OVA/
vehicle/OVA, (c) OVA/OVA/Sivelestat/OVA. (F) PAS staining (final magnification:x1000). (a) PBS/OVA/vehicle/OVA, (b) OVA/OVA/vehicle/OVA, (c)
OVA/OVA/Sivelestat/OVA. (G) The number of mucus-positive cells. Data represent the mean ± SD. (n = 8 in each group). *Significant differences
(P<0.05) between PBS/OVA/vehicle/OVA and OVA/OVA/vehicle/OVA. #Significant differences (P < 0.05) between OVA/OVA/vehicle/OVA
and OVA/OVA/Sivelestat/OVA.
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cytokine production from spleen cells
To determine whether the difference in cytokine levels
observed in the BAL fluid of mice treated with sivelestat
were due to a difference in antigen-specific T-cell re-
sponsiveness, spleen cells were isolated 6 hr after sec-
ondary OVA challenge, and re-stimulated in culture for
24 hrs with OVA. There were no significant differences
in cultures of cells from mice treated with sivelestat and
those treated with saline in for IFN-γ production. After
culture with OVA, spleen cells from mice treated with
sivelestat secreted significantly lower amounts of IL-13
than did spleen cells from mice treated with vehicle
(Figure 7).
Discussion
The main finding of this study is that a specific inhibitor of
neutrophil elastase, sivelestat, influences the lymphocytes,#
0
10
20
30
40
0
30
60
90
120
0
200
400
600
0
20
40
60
A B
D E
80
*
*
50
800
Figure 5 Treatment with sivelestat alters cytokine and growth factor
(A) IL-4, (B) IL-5, (C) IL-13, (D) TGF-β1, (E) Eotaxin, (F) KC, and (G) MIP-2 in B
the mean ± SD. (n = 16 in each group). *Significant differences (P<0.05) bet
differences (P < 0.05) between OVA/OVA/vehicle/OVA and OVA/OVA/Sivelewhich produce less IL-13, resulting in a decreased AHR
and airway inflammation. In the present study, we evalu-
ated the role of neutrophil elastase in allergen-induced in-
flammation and AHR on a background of previously
established disease, provoked by secondary challenge. This
model perhaps more closely mimics the human situation
of previous exposure than primary models of acute expos-
ure. We demonstrated that treatment with sivelestat admi-
nistered after primary sensitization and challenge but prior
to secondary challenge effectively prevented the triggering
of AHR, eosinophilic inflammation, Th2 cytokine produc-
tion and goblet cell metaplasia. The effects were similar
whether examined at 6 hr during a stage characterized by
neutrophilic inflammation and at 48 hr when eosinophilic
inflammation predominated.
Administration of house dust mite (HDM) by inhalation
was shown to induce airway inflammation without sys-
temic immunization. Rydell-Tormanen et al. demonstrated#
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Table 1 Concentrations of OVA-specific IgE in the serum
6 hrs (ng/ml) 48 hrs (ng/ml)
PBS/OVA/vehicle/OVA 5.5 ± 10.0 4.7 ± 9.4
OVA/OVA/vehicle/OVA 4682.1 ± 3919.8* 4182.8 ± 2819.6*
OVA/OVA/Sivelestat/OVA 4560.2 ± 2901.4 4855.6 ± 2101.6
Mice were sensitized and challenged as described in Methods. Serum levels of
anti-OVA IgE antibody were assessed 6 h and 48 h after the last airway
challenge. Mean values±SD are given (n = 8-12 in each group); PBS/OVA/
vehicle/OVA: non-sensitized but challenged mice followed by treatment with
vehicle; OVA/OVA/vehicle/OVA: sensitized and challenged mice followed by
treatment with vehicle; OVA/OVA/Sivelestat/OVA: sensitized and challenged
mice followed by treatment with sivelestat. *Significant differences (P<0.05)
PBS/OVA/vehicle/OVA and OVA/OVA/vehicle/OVA.
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http://respiratory-research.com/content/14/1/8that 20 weeks of HDM extract exposure resulted in a re-
duction in the proportion of eosinophils and an increase in
neutrophils compared with the inflammatory response
induced by 7 weeks, and that HDM extract exposure
induced airway and vascular remodeling [29]. Unlike OVA,
HDM extract is complex materials consisting of many pro-
tein and non-protein components, which are biochemically
active and may play a role in enhancing Th2 immune
responses. HDM allergens have proteinase activity, which
is critical for sensitization, and react with toll-like receptor
4 (TLR4) [30,31]. In addition, the group 2 major mite
allergen (Der f2) possesses structural homology to myeloid
differentiation factor (MD) 2, the lipopolysaccharide (LPS)-
binding component of the TLR4 signaling complex [32,33].
These findings indicate that HDM allergen sensitization
still involves complex interactions between antigen-specific
responses and innate immune responses that have not yet
been clarified. On the other hand, recent studies demon-
strated that different OVA-mouse models induced the neu-
trophilic allergic airway inflammation. Bobic et al. have
shown that IL-13 and IL-17 levels and the total cell counts
in BAL fluid were increased with higher neutrophil as well
as eosinophil, lymphocyte in Balb/c mice which were sensi-
tized with OVA by seven intraperitoneal injections and
exposed to aerosolized OVA for 8 subsequent days [34].
Nabe et al. have reported that in Balb/c mice which were
sensitized with OVA on days 0, 14 and 28, and challenged
by intratracheal administration of OVA on days 35, 36, 37
and 40, the numbers of neutrophils, which increased be-
fore and after the 2nd and 3rd challenges, returned to-
wards baseline prior to the 4th challenge, but showed
recurrent airway neutrophilia after the 4th challenge. Fur-
thermore, systemic treatment with the anti-Gr-1 monoclo-
nal antibody markedly suppressed 4th challenge-induced
airway neutrophilia and the induction of a late-phase in-
crease in AHR [35]. In the present study, mice developed a
two-phase airway inflammatory response after secondary
allergen challenge, one neutrophilic at 6 hr and the other
eosinophilic, at 48 hr. AHR to inhaled MCh was detected
at both phases of the response to secondary challenge. In
the first phase, 6 hr after last antigen challenge, micedeveloped AHR and a neutrophil-dominant airway inflam-
matory response with relatively small numbers of lympho-
cytes and eosinophils in the BAL fluid. Administration of
the neutrophil elastase inhibitor, sivelestat, reduced AHR
and the number of eosinophils and lymphocytes in the air-
ways. Of note, the numbers of neutrophils in BAL fluid
were only marginally reduced. In asthmatics [36] and in
animal models [37], neutrophils have been shown to be the
major inflammatory cells in the airways early after allergen
challenge. The timing of the peak neutrophil influx coin-
cided with development of AHR. The response to antigen
challenge at 48 hrs was characterized by a marked increase
in numbers of eosinophils, also accompanied by develop-
ment of AHR. Treatment with sivelestat similarly reduced
the numbers of eosinophils and suppressed AHR at this
point in time. Thus, inhibition of neutrophil elastase may
represent a novel therapeutic target. The results of our
study differ somewhat from with a previous study showing
that neutrophil elastase contributes to asthmatic responses
where a different sheep model of allergen-induced airway
responses was assessed using, nonetheless neutrophil elas-
tase inhibitor but did not affect the number of eosinophils
and lymphocytes in BAL fluid [18]. The basis for this dis-
crepancy is not clear but may reflect the use of a totally dif-
ferent protocol as well as model, using Ascaris suum
antigen in sheep. Moreover, the levels of cytokine, chemo-
kine and growth factors in the BAL fluid were not mea-
sured in the study.
To address the underlying mechanisms whereby neu-
trophil elastase inhibition affects allergen-induced airway
inflammation and AHR, BAL cytokine levels were
assayed. Although sivelestat did not affect levels of the
neutrophil chemoattractant, KC or MIP-2, it significantly
reduced the levels of BAL Th2 type cytokines, IL-4, IL-5
and IL-13, and eotaxin in BAL fluid 6 hr after secondary
allergen challenge. At 48 hr, treatment with sivelestat
significantly reduced the levels of IL-13 and TGF-β1 in
the BAL fluid. Assessment of in vitro Th2 cytokine pro-
duction from spleen cells after re-stimulation with OVA
confirmed that cells obtained from the mice which
received sivelestat treatment also produced lower levels
of IL-13 whereas levels of IFN-γ were unaffected. These
data suggest that inhibition of neutrophil elastase affects
Th2 cytokine production which, in turn, leads to reduc-
tion in allergic airway responses.
Protease-activated receptors (PARs) are a novel
family of G-protein-coupled receptors that are acti-
vated upon cleavage of the N terminus of the recep-
tor by proteases. This cleavage exposes a previously
cryptic, tethered ligand, which then binds intramo-
lecularly to the second extracellular loop to activate
the associated G-protein [38,39]. PARs are expressed
on a variety of cells including platelets, eosinophils,
neutrophils, mononuclear cells and epithelial cells in
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Figure 6 PAR-2 expression on lung tissue and T cells in PBLN. (A) PAR-2 stained lung tissue obtained 6hr and 48 hr after secondary
challenge (final magnification:x400). (a) 6 hr: PBS/OVA/vehicle/OVA, (b) 48 hr:PBS/OVA/vehicle/OVA, (c) 6 hr: OVA/OVA/vehicle/OVA, (d) 6 hr:OVA/
OVA/Sivelestat/OVA, (e) 48 hr: OVA/OVA/vehicle/OVA, (f) 48 hr: OVA/OVA/Sivelestat/OVA. (B) The number of PAR-2-positive cells. *Significant
differences (P<0.05) between PBS/OVA/vehicle/OVA and OVA/OVA/vehicle/OVA. Data represent the mean ± SD (n = 6 in each group). (C) Dotted
line: Control antibody, Thin line: anti-human PAR-2 mAb, Non/Non/Non, Bold line: anti-human PAR-2 mAb, OVA/OVA/OVA. PAR-2 expression of
CD3+ and CD4+ T Cells in PBLN. (a) CD3+ T cells in the PBLN and (b) CD4+ T Cells in PBLN were assessed by intracellular staining. The data shown
are representative of three independent experiments. Increased numbers of PAR-2 positive CD3+ and CD4+ T cells from the PBLN of the
sensitized and challenged mice were observed.
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http://respiratory-research.com/content/14/1/8the airway [40]. PAR-2 is one of the receptors for
the neutrophil elastase, which has been reported to
mediate eosinophil infiltration and AHR [41]. Neu-
trophil serine proteinases activate human nonepithe-
lial cells to produce inflammatory cytokines through
PAR-2 [25]. Since eosinophils express PAR-2 intracel-
lularly [28], neutrophil-derived serine proteases may
activate eosinophils [42]. We found that PAR-2 ex-
pression in the lung tissues was enhanced following
secondary challenge, and that PAR-2 intracellular ex-
pression on PBLN T cells was also increased follow-
ing allergen challenge of sensitized mice, suggestingthe involvement of PAR-2 in allergic airway responses.
In the present study, treatment with a specific inhibitor
of neutrophil elastase, sivelestat, did not alter the num-
ber of PAR-2 positive cells, nonetheless a PAR-2-
neutrophil elastase pathway may play an important
role in allergic inflammation since sivelestat effect-
ively prevented the triggering of AHR, eosinophilic
inflammation, Th2 cytokine production. Therefore,
additional mechanisms beyond PAR-2 positive cell
numbers but which involve PAR-2 pathways critical
to the development of allergic airway responses need
further investigation.
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Figure 7 Effect of neutrophil elastase inhibitor for in vitro cytokines production. In vitro cytokine production from spleen cells obtained
6 h after secondary challenge. The levels of (a) IL-4, (b) IL-5, (c) IL-13 and (d) IFN-γ in culture supernatant of spleen cells from mice after OVA
sensitization and challenge were measured. The results for each group are expressed as the mean ± SD. (n = 12 in each group). *P < 0.05 without
re-stimulation with OVA groups (medium) vs. with re-stimulation with OVA groups. #Significant differences (P < 0.05) between OVA/OVA/vehicle/
OVA and OVA/OVA/Sivelestat/OVA.
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http://respiratory-research.com/content/14/1/8Interestingly, Kikuchi et al. have shown that neutro-
phils enhance the trans-basement membrane migration
of eosinophils in vitro, therefore, activation of neutro-
phils may enhance the accumulation of eosinophils in
the airways, sustaining allergic inflammation [43]. LTB4,
a lipid mediator that is derived from membrane
phospholipid, is thought to play an important role in the
activation and recruitment of leukocytes, including neu-
trophils [44]. We have recently shown that chemoattrac-
tion and activation of neutrophils through LTB4-BLT1
may contribute, at least in part, to allergic airway inflam-
mation in established asthma [45]. Further understand-
ing of the relationship between neutrophils and
eosinophils, and between LTB4-BLT1 and the PAR-2-
neutrophil elastase pathway may help clarify the compli-
cated mechanisms of asthma development.
Mouse eotaxin has been shown to be a potent
chemoattractant for eosinophils during inflammation
and allergic reactions [46]. Eotaxin production by
bronchial epithelial cells was up-regulated by IL-4 and
IL-13, and attenuated by IFN-γ. In this study, eotaxin
levels in BAL fluid were increased 6 hrs after allergen
re-exposure in previously sensitized mice and signifi-
cantly decreased by treatment with the neutrophil elas-
tase inhibitor. Inhibition of IL-4 and IL-13 production
by the neutrophil elastase inhibitor may down-regulate
eotaxin secretion, thus suppressing migration of eosi-
nophils to the airways.After treatment with the neutrophil elastase inhibitor,
the levels of TGF-β1 in BAL fluid were also decreased.
It has been shown that IL-13 induces tissue fibrosis by
selectively stimulating and activating TGF-β1 and that
IL-13 action in concert with TGF-β1 may increase the
release of eotaxin from human fibroblasts [47,48].
Minshall et al. and ourselves demonstrated that TGF-β1
might play a role in the fibrotic changes occurring within
asthmatic airways, and that activated eosinophils were a
major source of this cytokine [49,50]. Thus, manipulating
neutrophil elastase may be effective for reducing airway
fibrotic changes and remodeling through suppression of
eosinophil activation and TGF-β1 secretion.
Conclusion
Administration of the neutrophil elastase inhibitor,
sivelestat, reduced AHR slightly but significantly in
mice with established airway disease and to reduce
BAL fluid Th2 cytokine, eotaxin and TGF-β1 levels
and goblet cell metaplasia. This was accompanied by
reducing eosinophils in the airways at the two distinct
phases of the response to secondary allergen challenge,
but not specific IgE level. Taken together, in both the
neutrophil- and eosinophil-dominant phases of the re-
sponse to secondary allergen challenge, the neutrophil
elastase inhibitor reduced AHR to inhaled methacholine
indicating the potential for its use as a modulator of the
immune/inflammatory response in established asthma.
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